QuidelOrtho Signs Lifotronic Deal to Add 25 Assays Across 70+ Platforms
QuidelOrtho entered a long-term supply agreement with Lifotronic Technology to access multiple low- to high-throughput immunoassay analyzer platforms and over 70 assays, including 25 new tests not on its VITROS systems. This deal expands its assay menu across Europe, Asia-Pacific and Latin America, potentially boosting recurring reagent revenue and international diversification.
1. Supply Agreement Details
QuidelOrtho has entered a long-term strategic supply agreement with Lifotronic Technology to expand its global immunoassay portfolio. The deal grants access to multiple analyzer platforms spanning low-, mid- and high-throughput settings, enhancing flexibility for laboratory deployments.
2. Expanded Assay Menu
Under the agreement, QuidelOrtho gains rights to a broad menu of over 70 assays, including more than 25 tests not currently available on its flagship VITROS systems. These assays cover routine and specialty diagnostics, supporting full-service laboratory tenders.
3. Strategic and Financial Impact
This partnership addresses key menu gaps and strengthens QuidelOrtho’s competitive position across Europe, Asia-Pacific and Latin America. With a $1.6 billion market capitalization, the company stands to drive incremental recurring reagent revenue and deepen international diversification.